BBNX

Notice to Pension Funds, Asset Managers, and Fiduciaries NEW YORK CITY, NY / ACCESS Newswire / October 16, 2026 / Levi & Korsinsky, LLP notifies institutional investors in Beta Bionics, Inc. (NASDAQ:BBNX) that a class action lawsuit has been filed on behalf of shareholders who purchased securities between July 30, 2025 and February 24, 2026. Request an institutional investor loss assessment. You may also contact Joseph E. Levi, Esq. at jlevi@levikorsinsky.com or (212) 363-7500.BBNX declined from a Class Period high of $31.99 to under $9.00 by April 10, 2026, a drop of approximately $23.09 per share, or 72%. Hundreds of millions of dollars in market capitalization were erased across the

Jefferies initiated coverage of Beta Bionics with a rating of Buy and set a new price target of $30.00

NEW YORK CITY, NY / ACCESS Newswire / October 9, 2026 / Levi & Korsinsky, LLP reminds purchasers of Beta Bionics, Inc. (NASDAQ:BBNX) securities that a class action is pending on behalf of shareholders who acquired shares between July 30, 2025 and February 24, 2026. See if you could be eligible to recover. You may also contact Joseph E. Levi, Esq. at jlevi@levikorsinsky.com or (212) 363-7500.From a Class Period high of $31.99 on January 8, 2026, BBNX shares fell to approximately $8.90 by April 10, 2026, a decline of $23.09 per share, or roughly 72%. The steepest single session took shares down 37%, or $11.85, to close at $20.14. Investors have until November 3, 2026 to seek lead plaintiff sta

SCHEDULE 13G - Beta Bionics, Inc. (0001674632) (Subject)

Barclays initiated coverage of Beta Bionics with a rating of Overweight and set a new price target of $30.00

4 - Beta Bionics, Inc. (0001674632) (Issuer)

IRVINE, Calif., Sept. 29, 2026 (GLOBE NEWSWIRE) -- Beta Bionics, Inc. (NASDAQ:BBNX), a pioneering leader in the development of advanced diabetes management solutions, today announced that it plans to release its third quarter 2026 financial results after the financial markets close on Tuesday, October 27, 2026. Management will host a conference call and concurrent webcast on the same day at 4:30 pm Eastern Time (1:30 pm Pacific Time), to review the company’s third quarter 2026 performance. The link to the webcast will be available on the Company’s website in the "Investors—Events & Presentations" section at https://investors.betabionics.com, and will be archived there for future replay. T

4 - Beta Bionics, Inc. (0001674632) (Issuer)

Wells Fargo initiated coverage of Beta Bionics with a rating of Overweight and set a new price target of $28.00

IRVINE, Calif., Sept. 22, 2026 (GLOBE NEWSWIRE) -- Beta Bionics, Inc. (NASDAQ:BBNX), a pioneering leader in the development of advanced diabetes management solutions, today announced a partnership to integrate the iLet Bionic Pancreas and mint automated insulin delivery (AID) systems with Senseonics’ Eversense 365 continuous glucose monitoring (CGM) system. Commercial launch of the integrated iLet and Eversense 365 system is expected in the fourth quarter of 2026, at which time Beta Bionics expects iLet to support the most CGM manufacturer options of any AID system, maximizing choice for its users. The companies have also committed to the integration of mint and Eversense 365 in the futu

4/A - Beta Bionics, Inc. (0001674632) (Issuer)

4 - Beta Bionics, Inc. (0001674632) (Issuer)

4 - Beta Bionics, Inc. (0001674632) (Issuer)

IRVINE, Calif., Sept. 17, 2026 (GLOBE NEWSWIRE) -- Beta Bionics, Inc. (NASDAQ:BBNX) today announced the closing of its previously announced underwritten public offering of 7,652,175 shares of its common stock at a price to the public of $17.25 per share and, in lieu of shares of common stock to certain investors, pre-funded warrants to purchase 1,043,484 shares of common stock at a purchase price of $17.2499 per share, which equals the public offering price per share of the common stock less the $0.0001 exercise price per share of each pre-funded warrant. In addition, the underwriters exercised their option in full and purchased 1,304,348 additional shares of common stock. Including the op

424B5 - Beta Bionics, Inc. (0001674632) (Filer)

FWP - Beta Bionics, Inc. (0001674632) (Subject)

IRVINE, Calif., Sept. 15, 2026 (GLOBE NEWSWIRE) -- Beta Bionics, Inc. (NASDAQ:BBNX) today announced the pricing of an underwritten public offering of 7,652,175 shares of its common stock at a price to the public of $17.25 per share and, in lieu of shares of common stock to certain investors, pre-funded warrants to purchase 1,043,484 shares of common stock at a purchase price of $17.2499 per share, which equals the public offering price per share of the common stock less the $0.0001 exercise price per share of each pre-funded warrant. The gross proceeds from this offering are expected to be $150.0 million, before deducting underwriting discounts and commissions and offering expenses payable

8-K - Beta Bionics, Inc. (0001674632) (Filer)

4 - Beta Bionics, Inc. (0001674632) (Issuer)

IRVINE, Calif., Sept. 15, 2026 (GLOBE NEWSWIRE) -- Beta Bionics, Inc. (NASDAQ:BBNX) today announced that it intends to offer and sell, in an underwritten public offering and subject to market and other conditions, $125.0 million of shares of its common stock. All of the shares are being offered by Beta Bionics. In addition, Beta Bionics intends to grant the underwriters for the offering a 30-day option to purchase up to an additional $18.75 million of the shares of its common stock offered in the public offering. There can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering. Beta Bionics expects to use the net proceeds fro

Mint features a new and innovative patch pump architecture Full Mint U.S. commercialization expected to begin in Q1 2027 Manufacturing capacity expected to produce at least 1.5 million disposable Mint units during 20273D Intelligence, the Company’s next-generation insulin dosing algorithm, has been submitted to the FDA through a 510(k) applicationExpectations to commercialize 3D Intelligence in the U.S. by the end of 2026 as iLet 3D™, and at the time of full Mint launch as Mint 3D™, subject to regulatory clearance by the FDAUpdated full year 2026 guidance IRVINE, Calif., Sept. 14, 2026 (GLOBE NEWSWIRE) -- Beta Bionics, Inc. (NASDAQ:BBNX), a pioneering leader in the development of advanced

Pairing year-long continuous glucose monitoring with automated insulin delivery to further simplify diabetes management for patients Brings Eversense 365 to the growing community of iLet Bionic Pancreas users Plan for commercial launch of the integrated system in Q4 2026 GERMANTOWN, Md., Sept. 14, 2026 (GLOBE NEWSWIRE) -- Senseonics Holdings, Inc. (NASDAQ:SENS), maker of the Eversense 365 Continuous Glucose Monitoring (CGM) System, the world’s first and only long-term, one-year implantable sensing technology, today announced a partnership with Beta Bionics, Inc (NASDAQ:BBNX), a pioneering leader in the development of advanced diabetes management solutions. The companies are collaboratin

4 - Beta Bionics, Inc. (0001674632) (Issuer)

4 - Beta Bionics, Inc. (0001674632) (Issuer)

4 - Beta Bionics, Inc. (0001674632) (Issuer)